Promotion of Th17 Polarized Immunity via Co-Delivery of Mincle Agonist and Tuberculosis Antigen Using Silica Nanoparticles-Reference-Cited by-同舟云学术

Promotion of Th17 Polarized Immunity via Co-Delivery of Mincle Agonist and Tuberculosis Antigen Using Silica Nanoparticles

Published:2024-06-04 Issue:6 Volume:7 Page:3877-3889
ISSN:2576-6422
Container-title:ACS Applied Bio Materials
language:en
Short-container-title:ACS Appl. Bio Mater.

Author:

Abdelwahab Walid M.¹²^ORCID,Le-Vinh Bao¹²,Riffey Alexander¹²,Hicks Linda¹²,Buhl Cassandra¹²,Ettenger George¹³,Jackson Konner J.¹²⁴,Weiss Adam M.¹²^ORCID,Miller Shannon¹²⁴,Ryter Kendal¹³⁴^ORCID,Evans Jay T.¹²⁴,Burkhart David J.¹²⁴

Affiliation:

1. Center for Translational Medicine, 32 campus drive, Missoula, Montana 59812, United States

2. Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Missoula, Montana 59812, United States

3. Department of Chemistry, University of Montana, 32 Campus Drive, Missoula, Montana 59812, United States

4. Inimmune Corporation, 1121 East Broadway, Missoula, Montana 59812, United States

Funder

National Institute of Allergy and Infectious Diseases

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsabm.4c00245

Reference43 articles.

1. Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?

2. What Have We Learnt about BCG Vaccination in the Last 20 Years?

3. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

4. Phase 2b Controlled Trial of M72/AS01EVaccine to Prevent Tuberculosis

5. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial